参考文献/References:
[1] Lund A,Knop FK,Vilsb?觟ll T．Emerging GLP-1 receptor agonists[J]．Expert Opin Emerg Drugs,2011,16（4）：607-618.
[2] Vilsb?觟ll T,Christensen M,Junker AE,et al．Effects of glucagon-like peptide-1 receptor agonists on weight loss：systematic review and meta-analyses of randomised controlled trials[J]．BMJ,2012,344：d7771.
[3] Ohki T,Isogawa A,Iwamoto M,et al．The effectiveness of liraglutide in nonalcoholic fatty liver disease patients with type 2 diabetes mellitus compared to sitagliptin and pioglitazone[J]．Sci World J,2012,2012：496453.
[4] Cuthbertson DJ,Irwin A,Gardner CJ,et al．Improved glycaemia correlates with liver fat reduction in obese,type 2 diabetes,patients given glucagon-like peptide-1 （GLP-1）receptor agonists[J]．PLoS One,2012,7（12）：e50117.
[5] Samson SL,Sathyanarayana P,Jogi M,et al．Exenatide decreases hepatic fibroblast growth factor 21 resistance in non-alcoholic fatty liver disease in a mouse model of obesity and in a randomised controlled trial[J]．Diabetologia,2011,54（12）：3093-3100.
[6] Sathyanarayana P,Jogi M,Muthupillai R,et al．Effects of com-bined exenatide and pioglitazone therapy on hepatic fat content in type 2 diabetes[J]．Obesity （Silver Spring）,2011,19（12）：2310-2315.
[7] Kelly AS,Bergenstal RM,Gonzalez-Campoy JM,et al．Effects of exenatide vs．metformin on endothelial function in obese patients with pre-diabetes：a randomized trial[J]．Cardiovasc Diabetol,2012,11：64.
[8] Klonoff DC,Buse JB,Nielsen LL,et al．Exenatide effects on diabetes, obesity,cardiovascular risk factors and hepatic biomark-ers in patients with type 2 diabetes treated for at least 3 years[J]．Curr Med Res Opin,2008,24（1）：275-286.
[9] Drucker DJ,Buse JB,Taylor K,et al．Exenatide once weekly versus twice daily for the treatment of type 2 diabetes：a randomised,open-label,non-inferiority study[J]．Lancet,2008,372（9645）：1240-1250.
[10] Bello NT,Kemm MH,Ofeldt EM,et al.Dose combinations of exendin-4 and salmon calcitonin produce additive and synergistic reductions in food intake in nonhuman primates[J]．Am J Physiol Regul Integr Comp Physiol,2010,299（3）：R945-R952.
[11] Jendle J,Nauck MA,Matthews DR,et al．Weight loss with liraglutide,a once-daily human glucagon-like peptide-1 analogue for type 2 diabetes treatment as monotherapy or added to metformin, is primarily as a result of a reduction in fat tissue[J]．Diabetes Obes Metab,2009,11（12）：1163-1172.
[12] Inoue K,Maeda N,Kashine S,et al．Short-term effects of liraglutide on visceral fat adiposity,appetite,and food preference： a pilot study of obese Japanese patients with type 2 diabetes[J]．Cardiovasc Diabetol,2011,10：109.
[13] Kelly AS,Rudser KD,Nathan BM,et al．The effect of glucagon-like peptide-1 receptor agonist therapy on body mass index in adolescents with severe obesity：a randomized,placebo-controlled, clinical trial[J]．JAMA,2013,167（4）：355-360.
[14] Hopkins ND,Cuthbertson DJ,Kemp GJ,et al．Effects of 6 months glucagon-like peptide-1 receptor agonist treatment on endothelial function in type 2 diabetes mellitus patients[J]．Diabetes Obes Metab,2013,15（8）：770-773.
[15] Ding X,Saxena NK,Lin S,et al．Exendin-4,a glucagon-like protein-1（GLP-1）receptor agonist,reverses hepatic steatosis in ob/ob mice[J]．Hepatology,2006,43（1）：173-181.
[16] Vendrell J,El Bekay R,Peral B,et al．Study of the potential association of adipose tissue GLP-1 receptor with obesity and insulin resistance[J]．Endocrinology,2011,152（11）：4072-4079.
[17] Gupta NA,Kolachala VL,Jiang R,et al．The glucagon-like peptide-1 receptor agonist exendin 4 has a protective role in ischemic injury of lean and steatotic liver by inhibiting cell death and stimulating lipolysis[J]．AM J Pathol,2012,181（5）：1693-1701.
[18] Gupta NA,Mells J,Dunham RM,et al．Glucagon-like peptide-1 receptor is present on human hepatocytes and has a direct role in decreasing hepatic steatosis in vitro by modulating elements of the insulin signaling pathway[J]．Hepatology,2010,51（5）：1584-1592.
[19] Trevaskis JL,Griffin PS,Wittmer C,et al．Glucagon-like pep-tide-1 receptor agonism improves metabolic, biochemical, and histopathological indices of nonalcoholic steatohepatitis in mice[J]．Am J Physiol Gastrointest Liver Physiol,2012,302（8）：G762-G772.
[20] Sharma S,Mells JE,Fu PP,et al．GLP-1 analogs reduce hepatocyte steatosis and improve survival by enhancing the unfolded protein response and promoting macroautophagy[J]． PLoS One,2011,6（9）：e25269.
[21] Ben-Shlomo S,Zvibel I,Shnell M,et al．Glucagon-like peptide-1 reduces hepatic lipogenesis via activation of AMP-activated protein kinase[J]．J Hepatol,2011,54（6）：1214-1223.
[22] Dushay J,Chui PC,Gopalakrishnan GS,et al．Increased fibrob-last growth factor 21 in obesity and nonalcoholic fatty liver disease[J]．Gastroenterology,2010,139（2）：456-463.
[23] Cnop M,Ladrière L,Igoillo-Esteve M,et al．Causes and cures for endoplasmic reticulum stress in lipotoxic beta-cell dysfunction[J]．Diabetes Obes Metab,2010,12 （Suppl 2）：76-82.
[24] 张学力,郗光霞,赵媛媛,等．艾塞那肽对糖耐量减低大鼠肝脏内质网应激标志性蛋白Ｃ/EBP同源蛋白表达的作用[J]．中国药物与临床,2012,2：167-169.
[25] Vanni E,Bugianesi E,Kotronen A,et al． From the metabolic syndrome to NAFLD or vice versa[J]?.Dig Liver Dis,2010,42（5）：320-330.